» Articles » PMID: 1581117

Introduction to Bone Biology

Overview
Journal Bone
Date 1992 Jan 1
PMID 1581117
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Bone at the tissue level undergoes remodeling: it is continuously being resorbed and rebuilt (or formed). A negative balance between bone resorption and formation, frequently due to excessive resorption, is the basis of many bone diseases. Resorption is carried out by osteoclasts, which are specialized multinucleated cells of hemopoietic origin. Bone resorption takes place at a specialized area of the osteoclast cell membrane called "ruffled border," which comprises a sealed lysosomal compartment where the acidic pH solubilizes the mineral and the proteolytic enzymes digest the matrix. Among the agents that inhibit bone resorption, only calcitonin and bisphosphonate have been shown to act directly on osteoclasts. Other hormones and agents, which modulate bone turnover, probably act on the osteoblasts or cells of the osteoblast lineage. Osteoblasts are bone-forming cells, originating from cells resident in bone committed to the osteoblastic lineage. They synthesize and secrete most of the proteins of the bone matrix, including type I collagen and noncollagenous proteins. They possess high levels of alkaline phosphatase, which participates in mineralization. Proteins, produced by osteoblasts, spill over into the blood and are used as indicators of bone formation. In addition to the matrix-forming ability, cells of the osteoblastic family (osteocytes, lining cells, and maybe other cells) participate in the regulation of bone turnover. They respond to parathyroid hormone, glucocorticoids, vitamin D, sex steroids, insulin, prostaglandins, growth factors, and so on. There are a significant number of cytokines, that are locally produced and may control bone resorption. These include prostaglandins, IL1, TNF alpha, possibily IL6.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Harnessing the potential of hyaluronic acid methacrylate (HAMA) hydrogel for clinical applications in orthopaedic diseases.

Lu J, Gao Z, He W, Lu Y J Orthop Translat. 2025; 50:111-128.

PMID: 39886531 PMC: 11779684. DOI: 10.1016/j.jot.2024.11.004.


Therapeutic Potential of Ginsenosides on Bone Metabolism: A Review of Osteoporosis, Periodontal Disease and Osteoarthritis.

Ko S Int J Mol Sci. 2024; 25(11).

PMID: 38892015 PMC: 11172997. DOI: 10.3390/ijms25115828.


Molecularly Imprinted Polymers: Shaping the Future of Early-Stage Bone Loss Detection-A Review.

Agnishwaran B, Manivasagam G, Udduttula A ACS Omega. 2024; 9(8):8730-8742.

PMID: 38434830 PMC: 10905706. DOI: 10.1021/acsomega.3c08977.


Emerging nano-scale delivery systems for the treatment of osteoporosis.

Dayanandan A, Cho W, Kang H, Bello A, Kim B, Arai Y Biomater Res. 2023; 27(1):68.

PMID: 37443121 PMC: 10347748. DOI: 10.1186/s40824-023-00413-7.


Polyoxyethylene Diamine Modification of Poly(amide-imide)-polyethylene Glycol Exhibits Excellent Hydrophilicity, Degradability, and Biocompatibility.

Yu R, Xu C, Wu X, Dai H Polymers (Basel). 2022; 14(21).

PMID: 36365687 PMC: 9657668. DOI: 10.3390/polym14214694.